NEW CELL AND CYTOKINE TARGETS II
Stem cell transplantation: a treatment option for severe systemic sclerosis?
1 Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle, UK
2 Service Medicine Interne, Hopital St Louis, Paris, France
3 Department of Rheumatology, University Hospital Basel, Basel, Switzerland
Correspondence to:
Professor J M van Laar, Musculoskeletal Research Group, Institute of Cellular Medicine, The Medical School, Cookson Building, Framlington Place, Newcastle NE2 4HH, UK; j.m.van-laar{at}ncl.ac.uk
High-dose immunosuppressive therapy and autologous stem cell transplantation (commonly referred to as "stem cell transplantation") is an established treatment for a variety of haemato-oncological conditions. Recent studies have confirmed its potent clinical and immunological effects in rheumatic autoimmune diseases, including severe diffuse systemic sclerosis (SSc). With modifications of treatment protocols and more stringent selection of patients, the safety profile of stem cell transplantation has improved as expressed in lower treatment-related morbidity and mortality. Prospective, randomised trials are in progress in Europe and North America to compare the safety and efficacy of stem cell transplantation with conventional chemotherapy in patients with early diffuse SSc, on the premise that induction of remission in early disease can be achieved by stem cell transplantation as a means to interrupt fibrogenesis.
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
